We are monitoring the impact of COVID-19 & Recession alarm on APAC Melanoma Therapeutics Market Get in touch with us for detailed analysis Know More
Share on

Asia Pacific Melanoma Therapeutics Market Research Report - Segmented By Cancer Stage, Cancer Type, Diagnosis, Treatment & Country (India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore & Rest of APAC) - Industry Analysis on Size, Share, Trends, COVID-19 Impact & Growth Forecast (2022 to 2027)

Published: January, 2022
ID: 795
Pages: 145

APAC Melanoma Therapeutics Market Size (2022 to 2027)

The size of the melanoma therapeutics market in the Asia Pacific was worth USD 0.91 billion in 2022 and is estimated to be growing at a CAGR of 16.40%, to reach USD 1.94 billion by 2027.

The melanoma market has seen an unparalleled boost in market size, owing to a vigorously developing nature of melanoma treatments over the recent past.

The elevated demand for innovative early-stage and advanced melanoma treatments along with a thriving patient base has generated an imminent need for improved therapies in the melanoma market. Even though many treatment choices are accessible today, various immunotherapies and combination therapies are anticipated to arrive on the market. Significant acceptance of these new treatments is projected due to their enhanced survival benefits and negligible side effects.

The growth of the Asia-Pacific Melanoma Therapeutics market is mainly due to the rise in melanoma cases and growing awareness towards it.

The APAC Melanoma therapeutics market is expected to be driven by the factors such as the increase in the incidences of melanoma cases among the people, growing awareness, and rising demand for melanoma therapeutics across the region. In addition, melanoma is one of the fastest-growing skin cancers in China, with high invasiveness and increased mortality rate among people is also expanding the market's growth.

In addition, the growing geriatric population, technological advancements in the treatment for developing innovative and enhanced therapies for treating melanoma are expected to fuel the market growth. Moreover, the initiatives taken by the government for creating healthcare awareness among the people are expected to influence the market growth positively.

On the other hand, the increasing investment and funding by the government and non-government for infrastructure development are expected to enable new market entrants. Key market players in the region are significantly focussing on the research activities for developing effective therapies and drugs for treating melanoma. The specific cause for this disease is more likely to provide lucrative growth opportunities for the market players. Exposure to ultraviolet radiation from the sunlight or beds raises the risk of developing melanoma. Also, the increasing awareness among people for pre-diagnosing the disease and its benefits are accelerating the growth rate of the APAC melanoma therapeutics market.

However, the increase in the high costs of the treatment and therapies of melanoma disease with the lack of poor reimbursements policies are restraining the market growth of the melanoma therapeutics market. In addition, the lack of accessing facilities and well-developed healthcare facilities are also hindering the market's growth. Furthermore, the strict government rules and regulations and stringent approval policies make the entry of the product more complex and hamper the market's growth. Also, the lack of awareness among the people about the treatment and therapies available in the market limits the development of melanoma therapeutics in the market in the APAC region.

This research report on the APAC melanoma therapeutics market has been segmented and sub-segmented into the following categories:

By Cancer Stage:

  • Stage 0
  • Stage I
  • Stage II
  • Stage III
  • Stage IV

By Cancer Type:

  • Nodular Melanoma
  • Acral Lentiginous Melanoma
  • Superficial Spreading Melanoma
  • Lentigno Maligna Melanoma
  • Amelanotic Melanoma
  • Others

By Diagnosis:

  • Ultrasound
  • Blood Tests
  • Dermatoscopy
  • Sentinel Lymph Node Biopsy
  • X-rays
  • CT Scan

By Treatment:

  • Early Melanoma
  • Advanced Melanoma-Biological Therapy
  • Targeted Therapy
  • Surgery
  • Chemotherapy
  • Radiotherapy
  • Immune Therapy

By Country:

  • India
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • Thailand
  • Malaysia
  • Vietnam
  • Philippines
  • Indonesia
  • Singapore
  • Rest of APAC

The Asia-Pacific Melanoma Therapeutics market is projected to grow at the highest CAGR during the forecast period due to reasons such as a large population base and the rising prevalence of melanoma. China is the largest market for Melanoma Therapeutics in this region, followed by India.

APAC countries such as China and India are estimated to have lucrative growth in the market due to a high population and the increase in the prevalence of rising melanoma cases in the region. Also, the rise in awareness about the effects and the factors that causes melanoma with the treatment and therapies available in the market is propelling the market growth.

In Australia, melanoma is the third most common cancer and other skin cancer, as skin cancer accounts for 80 percent of all newly diagnosed cancers every year. Therefore, the number of new cases of melanoma in 2022 is expected to grow by 5.8 percent, which will help increase the demand for the market growth of melanoma therapeutics.

KEY MARKET PLAYERS:

A few promising companies operating in the APAC melanoma therapeutics market profiled in this report are Bristol-Myers Squibb Co., Merck and Co., F. Hoffmann-La Roche, Amgen Inc., Celgene Corp, Daiichi Sankyo, and Pfizer Inc.

1. Introduction                             

              1.1 Market Definition                  

              1.2 Study Deliverables                

              1.3 Base Currency, Base Year and Forecast Periods                       

              1.4 General Study Assumptions              

2. Research Methodology                                       

              2.1 Introduction                           

              2.2 Research Phases                    

                             2.2.1 Secondary Research          

                             2.2.2 Primary Research

                             2.2.3 Econometric Modelling     

                             2.2.4 Expert Validation 

              2.3 Analysis Design                      

              2.4 Study Timeline                       

3. Overview                                   

              3.1 Executive Summary              

              3.2 Key Inferences                       

              3.3 New Developments              

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                

              4.1 Market Drivers                       

              4.2 Market Restraints                  

              4.3 Key Challenges                       

              4.4 Current Opportunities in the Market                           

5. Market Segmentation                                          

              5.1 By cancer stage                      

                             5.1.1 Stage 0     

                             5.1.2 Stage I      

                             5.1.3 Stage II     

                             5.1.4 Stage III   

                             5.1.5 Stage IV   

              5.2 By cancer type                        

                             5.2.1 Nodular melanoma           

                             5.2.2 Acral lentiginous melanoma          

                             5.2.3 Superficial spreading melanoma  

                             5.2.4 Lentigno maligna melanoma         

                             5.2.5 Amelanotic melanoma     

                             5.2.6 Others     

              5.3 By Diagnosis                           

                             5.3.1 Ultrasound            

                             5.3.2 Blood Tests           

                             5.3.3 Dermatoscopy      

                             5.3.4 Sentinel lymph node biopsy           

                             5.3.5 X-rays       

                             5.3.6 CT Scan    

              5.4 By Treatment                         

                             5.4.1 Early melanoma   

                             5.4.2 Advanced melanoma        

                                           5.4.2.1 Biological therapy

                                           5.4.2.2 Targeted therapy

                                           5.4.2.3 Surgery

                                           5.4.2.4 Chemotherapy

                                           5.4.2.5 Radiotherapy

                                           5.4.2.6 Immune therapy

6. Geographical Analysis                                         

              6.1 Introduction                           

              6.2 China                         

              6.3 India                          

              6.4 Japan                         

              6.5 South Korea                            

              6.6 Australia                   

7. Pipeline Product Analysis                                    

              7.1 Overview                                 

              7.2 Pipeline Development Landscape                                 

              7.3 Molecular Targets in the Pipeline                                  

              7.4 Clinical Trials                          

                             7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target    

                             7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target             

                             7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target.   

8. Strategic Analysis                                   

              8.1 PESTLE analysis                      

                             8.1.1 Political    

                             8.1.2 Economic

                             8.1.3 Social       

                             8.1.4 Technological       

                             8.1.5 Legal         

                             8.1.6 Environmental     

              8.2 Porter’s Five analysis                          

                             8.2.1 Bargaining Power of Suppliers       

                             8.2.2 Bargaining Power of Consumers   

                             8.2.3 Threat of New Entrants    

                             8.2.4 Threat of Substitute Products and Services             

                             8.2.5 Competitive Rivalry within the Industry     

9. Market Leaders' Analysis                                    

              9.1 Bristol-Myers Squibb Co                     

                             9.1.1 Overview 

                             9.1.2 Product Analysis  

                             9.1.3 Strategic Evaluation and Operations          

                             9.1.4 Financial analysis 

                             9.1.5 Legal issues           

                             9.1.6 Recent Developments       

                             9.1.7 SWOT analysis      

                             9.1.8 Analyst View         

              9.2 Merck and Co                         

              9.3 F. Hoffmann-La Roche                        

              9.4 Amgen Inc                

              9.5 Celgene Corp                          

              9.6 Daiichi Sankyo                        

              9.7 Pfizer Inc                   

10. Competitive Landscape                                     

              10.1 Market share analysis                      

              10.2 Merger and Acquisition Analysis                  

              10.3 Agreements, collaborations and Joint Ventures                    

              10.4 New Product Launches                     

11. Expert Opinions                                   

              11.1 Market Outlook                   

              11.2 Investment Opportunities               

Appendix                                       

              a) List of Tables              

              b) List of Figures           

  1. Asia-Pacific Melanoma Therapeutics Market By Region, From 2022 - 2027 (USD Billion)
  2. Asia-Pacific Melanoma Therapeutics Market By Cancer stage , From 2022 - 2027 (USD Billion)
  3. Asia-Pacific Stage 0 Market By Region, From 2022 - 2027 (USD Billion)
  4. Asia-Pacific Stage I Market By Region, From 2022 - 2027 (USD Billion)
  5. Asia-Pacific Stage II Market By Region, From 2022 - 2027 (USD Billion)
  6. Asia-Pacific Stage III Market By Region, From 2022 - 2027 (USD Billion)
  7. Asia-Pacific Stage IV Market By Region, From 2022 - 2027 (USD Billion)
  8. Asia-Pacific Melanoma Therapeutics Market By Cancer type , From 2022 - 2027 (USD Billion)
  9. Asia-Pacific Nodular melanoma Market By Region, From 2022 - 2027 (USD Billion)
  10. Asia-Pacific Acral lentiginous melanoma Market By Region, From 2022 - 2027 (USD Billion)
  11. Asia-Pacific Superficial spreading melanoma Market By Region, From 2022 - 2027 (USD Billion)
  12. Asia-Pacific Lentigno maligna melanoma Market By Region, From 2022 - 2027 (USD Billion)
  13. Asia-Pacific Amelanotic melanoma Market By Region, From 2022 - 2027 (USD Billion)
  14. Asia-Pacific Other cancers Market By Region, From 2022 - 2027 (USD Billion)
  15. Asia-Pacific Melanoma Therapeutics Market By Diagnosis, From 2022 - 2027 (USD Billion)
  16. Asia-Pacific Ultrasound Market By Region, From 2022 - 2027 (USD Billion)
  17. Asia-Pacific Blood Tests Market By Region, From 2022 - 2027 (USD Billion)
  18. Asia-Pacific Dermatoscopy Market By Region, From 2022 - 2027 (USD Billion)
  19. Asia-Pacific Sentinel lymph node biopsy Market By Region, From 2022 - 2027 (USD Billion)
  20. Asia-Pacific X-rays Market By Region, From 2022 - 2027 (USD Billion)
  21. Asia-Pacific CT Scan Market By Region, From 2022 - 2027 (USD Billion)
  22. Asia-Pacific Melanoma Therapeutics Market By Treatment, From 2022 - 2027 (USD Billion)
  23. Asia-Pacific early melanoma Market By Region, From 2022 - 2027 (USD Billion)
  24. Asia-Pacific advanced melanoma Market By Region, From 2022 - 2027 (USD Billion)
  25. Asia-Pacific Melanoma Therapeutics Market By Advanced Melanoma, From 2022 - 2027 (USD Billion)
  26. Asia-Pacific Biological therapy Market By Region, From 2022 - 2027 (USD Billion)
  27. Asia-Pacific Targeted therapy Market By Region, From 2022 - 2027 (USD Billion)
  28. Asia-Pacific Surgery Market By Region, From 2022 - 2027 (USD Billion)
  29. Asia-Pacific Chemotherapy Market By Region, From 2022 - 2027 (USD Billion)
  30. Asia-Pacific Radiotherapy Market By Region, From 2022 - 2027 (USD Billion)
  31. Asia-Pacific Immune therapy Market By Region, From 2022 - 2027 (USD Billion)
  32. China Melanoma Therapeutics Market By Cancer stage , From 2022 - 2027 (USD Billion)
  33. China Melanoma Therapeutics Market By Cancer type , From 2022 - 2027 (USD Billion)
  34. China Melanoma Therapeutics Market By Diagnosis, From 2022 - 2027 (USD Billion)
  35. China Melanoma Therapeutics Market By Treatment, From 2022 - 2027 (USD Billion)
  36. China Melanoma Therapeutics Market By Advanced Melanoma, From 2022 - 2027 (USD Billion)
  37. India Melanoma Therapeutics Market By Cancer stage , From 2022 - 2027 (USD Billion)
  38. India Melanoma Therapeutics Market By Cancer type , From 2022 - 2027 (USD Billion)
  39. India Melanoma Therapeutics Market By Diagnosis, From 2022 - 2027 (USD Billion)
  40. India Melanoma Therapeutics Market By Treatment, From 2022 - 2027 (USD Billion)
  41. India Melanoma Therapeutics Market By Advanced Melanoma, From 2022 - 2027 (USD Billion)
  42. Japan Melanoma Therapeutics Market By Cancer stage , From 2022 - 2027 (USD Billion)
  43. Japan Melanoma Therapeutics Market By Cancer type , From 2022 - 2027 (USD Billion)
  44. Japan Melanoma Therapeutics Market By Diagnosis, From 2022 - 2027 (USD Billion)
  45. Japan Melanoma Therapeutics Market By Treatment, From 2022 - 2027 (USD Billion)
  46. Japan Melanoma Therapeutics Market By Advanced Melanoma, From 2022 - 2027 (USD Billion)
  47. South Korea Melanoma Therapeutics Market By Cancer stage , From 2022 - 2027 (USD Billion)
  48. South Korea Melanoma Therapeutics Market By Cancer type , From 2022 - 2027 (USD Billion)
  49. South Korea Melanoma Therapeutics Market By Diagnosis, From 2022 - 2027 (USD Billion)
  50. South Korea Melanoma Therapeutics Market By Treatment, From 2022 - 2027 (USD Billion)
  51. South Korea Melanoma Therapeutics Market By Advanced Melanoma, From 2022 - 2027 (USD Billion)
  52. Australia Melanoma Therapeutics Market By Cancer stage , From 2022 - 2027 (USD Billion)
  53. Australia Melanoma Therapeutics Market By Cancer type , From 2022 - 2027 (USD Billion)
  54. Australia Melanoma Therapeutics Market By Diagnosis, From 2022 - 2027 (USD Billion)
  55. Australia Melanoma Therapeutics Market By Treatment, From 2022 - 2027 (USD Billion)
  56. Australia Melanoma Therapeutics Market By Advanced Melanoma, From 2022 - 2027 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

PURCHASE OPTIONS

excel
$

3335


pdf excel
$

3677


pdf excel powerbi
$

5520


excel
$

2000

What You Get :

  • PDF Report Format.
  • Can be accessible by 1 single user.
  • 6 Months of Free Analyst Support.
  • PDF and Excel Datasheet Formats.
  • Can be accessible upto 2 to 5 users.
  • 1 Year of Free Analyst Support.
  • PDF, Excel and Power BI Dashboard.
  • Can be accessible by unlimited users.
  • 1 Year of Free Analyst Support.
  • Excel Datasheet Format.
  • Customized access as per user request.
  • Upgradable to other licenses.
customer-support
ASK FOR CUSTOMIZATION

Talk to our analyst and get customised report done according to your research needs

tag
INQUIRE FOR DISCOUNT

Check if you can avail any discount. Submit your details and our team will get back to you.

cloud-download
DOWNLOAD FREE SAMPLE

Request to avail a free sample report that reflects this market and its growth.

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 3335

Didn’t find what you’re looking for?
TALK TO OUR TEAM

Find it too expensive?
NO WORRIES!

Click for Request Sample